TRIUMPH-1 the pivotal general obesity trial with 2,339 patients followed for 80 weeks also reported dysesthesia, confirming this side effect occurs across different patient populations, not just osteoarthritis patients
External resources NEJM: Triple Hormone-Receptor Agonist Retatrutide for Obesity Phase 2 Trial PMC: Retatrutide - A Game Changer in Obesity Pharmacotherapy PMC: Efficacy and Safety of Retatrutide - Systematic Review and Meta-Analysis American Diabetes Association: Retatrutide Clinical Highlights Nature Medicine: Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease For researchers serious about optimizing their retatrutide protocols, SeekPeptides offers the most comprehensive resource available, with evidence-based guides, proven protocols, personalized dosing tools, and a community of thousands who have navigated these exact decisions
Alternative administration routes like intranasal delivery are being explored in some research contexts, though subcutaneous injection remains the standard based on clinical trial protocols
Lean mass initially decreased by approximately 3 kg and then stabilized
For someone weighing 220 pounds, a 24% reduction means roughly 53 pounds lost with Retatrutide, while a 12% reduction with Ozempic would mean about 26 pounds
They show promise as adjunctive therapy in sepsis due to their anti-inflammatory, antioxidant, and endothelial-protective actions
